Document is current
Any future updates will be listed below
-
Authors
Livesey, Benjamin J.
Badonyi, Mihaly
Dias, Mafalda
Frazer, Jonathan
Kumar, Sushant
Lindorff-Larsen, Kresten
McCandlish, David M.
Orenbuch, Rose
Shearer, Courtney A.
Muffley, Lara
Foreman, Julia
Glazer, Andrew M.
Lehner, Ben
Marks, Debora S.
Roth, Frederick P.
Rubin, Alan F.
Starita, Lea M.
Marsh, Joseph A.
-
Funding
Funding for this research was provided by:
Medical Research Council (MC_UU_00035/9, MC_UU_00035/9)
European Research Council (101001169, 883742, 101001169)
Ministerio de Ciencia e Innovación (PID2022-140793NA-I00, PID2022-140793NA-I00)
Novo Nordisk Fonden (NNF18OC0033950)
National Institutes of Health (R35GM133613, RM1HG010461, 1R01CA260415, RM1HG010461, RM1HG010461)
Chan Zuckerberg Initiative (CZI2018-191853, CZI2018-191853)
Wellcome Trust (WT223718/Z/21/Z)
Center for Information Technology (R01HG013025)
- License Information
-
More Information
Article History
Received: 26 May 2024
Accepted: 8 April 2025
First Online: 15 April 2025
Declarations
:
: Not applicable.
: F.P.R. is a shareholder and advisor for Constantiam Biosciences, Inc.
